

Comment on Grob et al, page 2347


# TP53 and the star-crossed lovers MDS and AML

John S. Welch | Washington University School of Medicine

**In this issue of *Blood*, Grob et al<sup>1</sup> integrate mutational analysis with clinical outcomes and propose merging TP53-mutated myelodysplastic syndrome with excess blasts (MDS-EB; bone marrow blasts 5% to 19%) and TP53-mutated acute myeloid leukemia (AML) into a unified diagnosis. They evaluate mutations in 2200 patients with AML or MDS-EB (International Prognostic Scoring System [IPSS]  $\geq 1.5$  or IPSS-revised (IPSS-R)  $> 4.5$ ) who were treated in clinical trials in the Haemato-Oncology Foundation for Adults in the Netherlands and the Swiss Group for Clinical Research (HOVON-SAKK) from 2001 through 2017. They identify 283 TP53 mutations in 230 patients (186 patients with AML and 44 patients with MDS-EB). Across multiple clinical parameters, they found no significant difference between the patients with TP53-mutated AML or TP53-mutated MDS-EB (age, sex, white blood cell counts, remission rates, consolidation treatment, allelic status, number of TP53 mutations, TP53 clone size, concurrent mutation patterns, or survival outcomes).**

As a junior Hematology/Oncology fellow, I was told there were 2 types of physicians: splitters and mergers. That is, clinicians either seek to diagnose increasingly homogeneously narrow groups of patients based on increasingly refined, shared characteristics, or they seek to find broad, overarching patterns that unite diagnostic classifications. Hematologic malignancies have been fertile ground for the diagnostic splitters of the

world. On the other hand, there have been some noteworthy exceptions. Sometimes it is a technological advance that allows for the synthesis of disparate diagnoses. Paul Ehrlich's cell staining techniques combined with improved microscopy allowed 19th-century clinicians to recognize shared features in splenic and myelogenous leukemias, unifying these diagnoses. Sometimes it is thoughtful speculation. William Damashek



AML and MDS represent related diagnoses of clonal myeloid disorders. Grob and colleagues report that in patients with AML or MDS with TP53 mutations clinical characteristics and outcomes are overlapping and propose that these 2 diseases be considered as a single diagnosis.

surveyed diverse clinical presentations and proposed a shared structure to myeloproliferative neoplasms. Grob and colleagues propose an interesting union of diagnoses (see figure).

The diagnostic separation of MDS and AML has been the subject of changing guidelines. In the French-American-British schema, MDS and AML were separated by an arbitrary threshold of 30% bone marrow blasts, later revised in the World Health Organization classification to 20%, and MDS has been variably subcategorized further based on cytopenias, bone marrow blast counts, dysplastic morphology, and recurrent cytogenetics.

Genome sequencing has revealed striking shared features between MDS and AML. MDS and AML share a similar degree of disease burden in the bone marrow, with mutation variant allele frequencies which often suggest that most of the bone marrow cells are involved in the malignant clone, even in cases of MDS with low or absent blasts.<sup>2</sup> MDS and AML also share overlapping mutational and cytogenetic patterns, even if some mutations may be more biased toward one diagnosis or the other (MDS: spliceosome and cohesin mutations; AML: *NPM1*, 11q23 rearrangements, core-binding factor mutations). Based on clinical progression and survival patterns, researchers have proposed merging low blast count MDS (blasts  $< 2\%$ ) and clonal cytopenias of undetermined significance (CCUS) into a unified category of clonal cytopenias, whereas higher blast count MDS (2% to 19%) could be merged with AML into a disorder of oligoblastic leukemia.<sup>3,4</sup>

Diagnostic separation of MDS-EB and AML can be technically challenging. Variance in bone marrow collection quality and hematopathology analysis leads to discrepancies between repeat analysis of prepared slides and between repeat aspirates, and a second bone marrow evaluation has been associated with disease upstaging in 10% to 15% of MDS.<sup>5</sup> A clear diagnostic separation within TP53-mutant diseases may be even more challenging. Consistent with other datasets, Grob and colleagues observed that TP53-mutated AML tends to present with lower white blood cell counts and lower bone marrow blast counts than TP53 wild-type AML. In MDS, the

opposite has been observed,<sup>6</sup> and patients with the *TP53* mutation tend to have higher blast counts than their wild-type counterparts. Thus, *TP53*-mutant MDS and *TP53*-mutant AML may represent a technical diagnostic continuum.

Despite overlapping features, *TP53* mutations may not be sufficient to independently form a unifying diagnosis of cases across all myeloid disorders (clonal hematopoiesis of indeterminate prognosis [CHIP], CCUS, myeloproliferative neoplasm, chronic myelomonocytic leukemia [CMML], MDS, and AML). *TP53* mutations are associated with more rapid progression in patients with CHIP and in myeloproliferative diseases compared with patients with wild-type *TP53*, but those with CHIP or with *TP53* mutations appear to have longer survival than their counterparts with MDS or AML.<sup>7,8</sup> Unlike patients with MDS or AML, those with CMML with *TP53* mutations do not commonly have co-occurring complex karyotypes.<sup>9</sup> Also, not all *TP53* mutations are created equally; most are missense variants that occur at a series of hotspot nucleotides and may be associated with second mutations, loss of heterozygosity, or deletion of the alternate allele. Some have suggested that more deleterious mutations may be associated with dominant-negative or gain-of-function effects, which induce more rapid clinical progression than isolated deletion or nonsense variants.<sup>10</sup>

Why does a name matter? Juliet famously pines for unity with her Romeo, “What is in a name? ... Doff thy name, and for that name which is no part of thee, take all myself.” But Romeo cannot shed his Montague heritage, even when bound to her gentleness. Outcomes for *TP53*-MDS and -AML are poor, and treatment options are limited. Bringing these diseases together may increase the number of related cases that can be analyzed in individual datasets and may enable more consistent enrollment onto *TP53*-mutant-focused clinical trials. Also, as a name, “dysplastic syndrome” does not convey the perilous journey that lies ahead for a patient with *TP53*-mutated MDS. In the end, Romeo and Juliet find themselves sealed together in a tomb of tragedy, and their families are admonished to “know their true descent ... meantime forebear and let mischance be slave to patience.” Perhaps it is time to bring these star-crossed lovers

together in their own house, and patiently seek the instruments, “fit to open these dead men’s tombs.” “O brother Montague, give me thy hand.”

*Conflict-of-interest disclosure:* J.S.W. receives research support from Janssen Pharmaceuticals and Notable Labs. ■

## REFERENCES

1. Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant *TP53* acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood*. 2022;139(15):2347-2354.
2. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1090-1098.
3. Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. *Blood*. 2019;133(10):1086-1095.
4. Lichtman MA. Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of

myelodysplasia. *Oncologist*. 2013;18(9):973-980.

5. Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. *Blood*. 2011;118(17):4690-4693.
6. Hou HA, Chou WC, Kuo YY, et al. *TP53* mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. *Blood Cancer J*. 2015;5(7):e331.
7. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood*. 2014;123(14):2220-2228.
8. Silver AJ, Jaiswal S. Clonal hematopoiesis: pre-cancer PLUS. *Adv Cancer Res*. 2019;141:85-128.
9. Wang W, Routbort MJ, Loghavi S, Tang Z, Medeiros LJ, Wang SA. Characterization of chronic myelomonocytic leukemia with *TP53* mutations. *Leuk Res*. 2018;70:97-99.
10. Dutta S, Pregartner G, Rucker FG, et al. Functional classification of *TP53* mutations in acute myeloid leukemia. *Cancers (Basel)*. 2020;12(3):637.

DOI 10.1182/blood.2022015709

© 2022 by The American Society of Hematology

## PLATELETS AND THROMBOPOIESIS

Comment on Farley et al, page 2355

# With age comes resilience

David B. Wilson and Melanie E. Fields | Washington University School of Medicine

**In this issue of *Blood*, Farley et al<sup>1</sup> use a mouse model of fetal and neonatal alloimmune thrombocytopenia (FNAIT) to show how risk of intracranial hemorrhage (ICH) varies with platelet count and developmental age. In addition to delineating critical platelet thresholds, they demonstrate that mice develop resilience to thrombocytopenia-associated ICH shortly after birth.**

FNAIT results from placental transfer of maternal alloantibodies (IgGs) directed against paternally inherited antigens present on fetal platelets but absent from maternal platelets.<sup>2,3</sup> These alloantibodies trigger accelerated clearance of platelets from the fetal and neonatal circulation. Hence, this condition is the platelet counterpart of hemolytic disease of the newborn. FNAIT occurs in ≈1 of every 1000 live births and is 1 of the principal causes of severe thrombocytopenia (platelet count <25 × 10<sup>9</sup>/L) in fetuses and term newborns.<sup>2-4</sup> Notably, approximately 15% of affected neonates have ICH (see figure panel A), and 50% of these cases occur antenatally. Among the long-term consequences of ICH

in the ante- or neonatal period are hydrocephalus, porencephaly, seizures, and fetal demise. Treatment of FNAIT includes antenatal IV IgG to suppress platelet destruction and postnatal platelet transfusion.<sup>2,3</sup>

Currently, there are more than 30 known human platelet alloantigens (HPAs) expressed on surface glycoprotein (GP) complexes including GPIIb/IIIa (fibrinogen receptor), GP1b-V-IX (von Willebrand factor receptor), and GP1a/IIa (collagen receptor).<sup>2,3</sup> In populations of European ancestry, the alloantigen most frequently implicated in FNAIT is HPA-1a, an epitope on GPIIIa, accounting for about 80% of cases. GPIIIa is expressed